Vivosim Lab Inc (VIVS)

$0.28 -0.04 (-12.39%)
Market Cap 3.83M
Revenue (ttm) 130,000.00
Net Income (ttm) -13.84M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -10,646.15%
Debt to Equity Ratio 0.00
Volume 2,054,200
Avg Vol 6,959,428
Day's Range N/A - N/A
Shares Out 12.06M
Stochastic %K 5%
Beta 1.47
Analysts Strong Buy
Price Target $64.83

Company Profile

VivoSim Labs, Inc., a pharmaceutical and biotechnology services company, provides testing of drugs and drug candidates in three-dimensional (3D) human tissue models of liver and intestine. It offers partners liver and intestinal toxicology insights through its new approach methodologies (NAM) models; and bespoke services in the areas of investigational toxicology, mechanism of drug action elucidation, and other applications of complex human tissue models. The company also provides liver toxicolo...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 224 1000
Website: vivosim.ai
Address:
11555 Sorrento Valley Road, Suite 100, San Diego, United States
NetNinja
NetNinja Aug. 18 at 11:16 PM
$VIVS Just waiting for the inevitable R/S.
1 · Reply
itsStocksOver
itsStocksOver Aug. 18 at 8:28 PM
$VIVS bagged at 0.32 f this pos
1 · Reply
tomorrowsglory
tomorrowsglory Aug. 18 at 8:05 PM
$VIVS Low Volume Today!
0 · Reply
BigJuanOTC
BigJuanOTC Aug. 18 at 8:02 PM
$VIVS low volume snooze fest today…..
0 · Reply
Zboquid
Zboquid Aug. 18 at 8:01 PM
$VIVS
0 · Reply
valdekio
valdekio Aug. 18 at 7:14 PM
$VIVS Going down like a one legged hooker.
0 · Reply
ChillingTrader
ChillingTrader Aug. 18 at 5:35 PM
$VIVS 1. As of August 3, 2026, the Company's cash on hand was approximately $10.1 million 2.VivoSim expects FY27 revenue growth of over 500%, receives $5M milestone payment from Eli Lilly 3. VivoSim remains eligible for up to $45 million in additional milestone payments 4.4 million MC?????
0 · Reply
Zboquid
Zboquid Aug. 18 at 4:25 PM
$VIVS
0 · Reply
itsStocksOver
itsStocksOver Aug. 18 at 3:15 PM
$VIVS should run to 0.4 soon and then dump to rs
0 · Reply
Staker58
Staker58 Aug. 18 at 2:49 PM
$VIVS this one is toast
0 · Reply
Latest News on VIVS
VivoSim Provides Financial and Listing Compliance Update

Aug 6, 2026, 8:05 AM EDT - 13 days ago

VivoSim Provides Financial and Listing Compliance Update

VIVS

VivoSim Enters China with First Commercial Sales of NAMkind™ Toxicology Screening and Efficacy Testing Services

Jul 21, 2026, 8:05 AM EDT - 4 weeks ago

VivoSim Enters China with First Commercial Sales of NAMkind™ Toxicology Screening and Efficacy Testing Services

VIVS

VivoSim Announces Pricing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules with a Single Healthcare Focused Institutional Investor

Jul 16, 2026, 8:30 AM EDT - 4 weeks ago

VivoSim Announces Pricing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules with a Single Healthcare Focused Institutional Investor

VIVS

VivoSim Receives $5M Milestone Payment from Eli Lilly; Provides Guidance That It Expects Revenue Growth of 500%+ in FY2027

Jul 15, 2026, 8:05 AM EDT - 5 weeks ago

VivoSim Receives $5M Milestone Payment from Eli Lilly; Provides Guidance That It Expects Revenue Growth of 500%+ in FY2027

VIVS

VivoSim Presents Data Showing Superiority to Competition in NAM Liver Tox Prediction at European Toxicology Meeting

Jun 29, 2026, 8:05 AM EDT - 7 weeks ago

VivoSim Presents Data Showing Superiority to Competition in NAM Liver Tox Prediction at European Toxicology Meeting

VIVS

VivoSim Platform Predicts Gastrointestinal Toxicity (Diarrhea) in an AI Model Trained on Human Intestinal Model Results – Without Animal Testing

Apr 28, 2026, 8:05 AM EDT - 4 months ago

VivoSim Platform Predicts Gastrointestinal Toxicity (Diarrhea) in an AI Model Trained on Human Intestinal Model Results – Without Animal Testing

VIVS

VivoSim Announces Pricing of up to a $4 Million Public Offering

Apr 1, 2026, 8:05 AM EDT - 5 months ago

VivoSim Announces Pricing of up to a $4 Million Public Offering

VIVS

VivoSim Releases Antibody Drug Conjugate (ADC) Data Showing Power to Detect ADC Toxicity and Guide Design of Safer ADCs

Mar 24, 2026, 8:05 AM EDT - 5 months ago

VivoSim Releases Antibody Drug Conjugate (ADC) Data Showing Power to Detect ADC Toxicity and Guide Design of Safer ADCs

VIVS

VivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global Sales

Mar 3, 2026, 8:05 AM EST - 6 months ago

VivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global Sales

VIVS

VivoSim to Debut Antibody Drug Conjugate Data, representing a major new market for NAMkind models, at Society of Toxicology Meeting in San Diego

Feb 11, 2026, 8:05 AM EST - 6 months ago

VivoSim to Debut Antibody Drug Conjugate Data, representing a major new market for NAMkind models, at Society of Toxicology Meeting in San Diego

VIVS

VivoSim Expands Asia-Pacific Access to NAMKind™ Human-Based Toxicology Services Through New Distributor Agreement in Korea and China

Jan 29, 2026, 4:05 PM EST - 7 months ago

VivoSim Expands Asia-Pacific Access to NAMKind™ Human-Based Toxicology Services Through New Distributor Agreement in Korea and China

VIVS

VivoSim Labs Appoints Amar Sethi, M.D., Ph.D. as Chief Scientific Officer

Jan 6, 2026, 8:05 AM EST - 8 months ago

VivoSim Labs Appoints Amar Sethi, M.D., Ph.D. as Chief Scientific Officer

VIVS

VivoSim Labs Appoints Tony Lialin as Chief Commercial Officer

Aug 14, 2025, 8:05 AM EDT - 1 year ago

VivoSim Labs Appoints Tony Lialin as Chief Commercial Officer

VIVS

VivoSim's NAMKind™ Intestine Wins Blue Ribbon Award at Digestive Disease Week Conference

May 13, 2025, 8:05 AM EDT - 1 year ago

VivoSim's NAMKind™ Intestine Wins Blue Ribbon Award at Digestive Disease Week Conference

VIVS

VivoSim Presents Best-in-Class Liver Toxicology Prediction Results at Digestive Disease Week Conference

May 7, 2025, 8:05 AM EDT - 1 year ago

VivoSim Presents Best-in-Class Liver Toxicology Prediction Results at Digestive Disease Week Conference

VIVS

VivoSim Announces Emergence from Stealth Mode To Provide Technologies for FDA Turn Away from Animal Models, $10B+ Market

Apr 24, 2025, 8:05 AM EDT - 1 year ago

VivoSim Announces Emergence from Stealth Mode To Provide Technologies for FDA Turn Away from Animal Models, $10B+ Market

VivoSim to Carry Forward Organovo 3D Bioprinting

Apr 23, 2025, 8:05 AM EDT - 1 year ago

VivoSim to Carry Forward Organovo 3D Bioprinting

Organovo Provides Update on Cash and Nasdaq Continued Listing Requirements

Apr 2, 2025, 8:05 AM EDT - 1 year ago

Organovo Provides Update on Cash and Nasdaq Continued Listing Requirements

Organovo Provides Business Update

Mar 27, 2025, 8:05 AM EDT - 1 year ago

Organovo Provides Business Update

Organovo Announces Close of the Sale of FXR Program to Eli Lilly and Company

Mar 25, 2025, 11:25 AM EDT - 1 year ago

Organovo Announces Close of the Sale of FXR Program to Eli Lilly and Company

LLY

Organovo Announces Reverse Stock Split

Mar 19, 2025, 8:05 AM EDT - 1 year ago

Organovo Announces Reverse Stock Split

Matinas BioPharma Appoints Seasoned Biotech Leaders to Board of Directors

Mar 11, 2025, 7:00 AM EDT - 1 year ago

Matinas BioPharma Appoints Seasoned Biotech Leaders to Board of Directors

GRCE MTNB

Organovo Announces the Issuance of Additional Shares in Conjunction with Warrant Exercises

Mar 6, 2025, 8:05 AM EST - 1 year ago

Organovo Announces the Issuance of Additional Shares in Conjunction with Warrant Exercises

Organovo's FXR Program, including FXR314, to Be Acquired by Eli Lilly and Company

Feb 25, 2025, 8:05 AM EST - 1 year ago

Organovo's FXR Program, including FXR314, to Be Acquired by Eli Lilly and Company

Organovo Announces Appointment of Norman Staskey as Chief Financial Officer

Jan 6, 2025, 8:05 AM EST - 1 year ago

Organovo Announces Appointment of Norman Staskey as Chief Financial Officer

Organovo Presents Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting

Nov 20, 2024, 8:05 AM EST - 1 year ago

Organovo Presents Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting

Organovo to Present Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting Sponsored by the American Association for the Study of Liver Diseases

Nov 13, 2024, 8:06 AM EST - 1 year ago

Organovo to Present Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting Sponsored by the American Association for the Study of Liver Diseases

Organovo Highlights FXR314 Near Term Value Catalysts at Jones Trading Conference Strong Preclinical and Human Rationale for FXR314 in P2 2 Ulcerative Colitis

Jul 16, 2024, 8:05 AM EDT - 2 years ago

Organovo Highlights FXR314 Near Term Value Catalysts at Jones Trading Conference Strong Preclinical and Human Rationale for FXR314 in P2 2 Ulcerative Colitis

Organovo Data Presented at Digestive Disease Week (DDW2024) Demonstrating Potential for FXR314 as Combination Therapy with Tofacitinib for Inflammatory Bowel Disease

May 21, 2024, 8:05 AM EDT - 2 years ago

Organovo Data Presented at Digestive Disease Week (DDW2024) Demonstrating Potential for FXR314 as Combination Therapy with Tofacitinib for Inflammatory Bowel Disease

Organovo to Present Data on FXR314 at Digestive Diseases Week (DDW2024)

May 14, 2024, 11:00 AM EDT - 2 years ago

Organovo to Present Data on FXR314 at Digestive Diseases Week (DDW2024)

Organovo Holdings, Inc. Announces Pricing of $5.25 Million Public Offering

May 8, 2024, 8:00 PM EDT - 2 years ago

Organovo Holdings, Inc. Announces Pricing of $5.25 Million Public Offering

Organovo's fatty liver disease drug meets main goal in mid-stage study

Apr 15, 2024, 8:28 AM EDT - 2 years ago

Organovo's fatty liver disease drug meets main goal in mid-stage study

Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo

Apr 15, 2024, 8:05 AM EDT - 2 years ago

Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo

Organovo Presents FXR314 3D Human Tissue Model Findings That Show Improved Epithelial Barrier Function and Fibrosis Reduction at Crohn's and Colitis Congress

Jan 25, 2024, 8:05 AM EST - 2 years ago

Organovo Presents FXR314 3D Human Tissue Model Findings That Show Improved Epithelial Barrier Function and Fibrosis Reduction at Crohn's and Colitis Congress

Organovo To Present FXR314 IBD 3D Model Findings at Upcoming Crohn's and Colitis Congress

Jan 9, 2024, 8:05 AM EST - 2 years ago

Organovo To Present FXR314 IBD 3D Model Findings at Upcoming Crohn's and Colitis Congress

Organovo Provides Timing for Release of FXR314 Phase 2 NASH Results

Dec 6, 2023, 8:05 AM EST - 2 years ago

Organovo Provides Timing for Release of FXR314 Phase 2 NASH Results

CORRECTION – Organovo Highlights FXR314 Combination Therapy Potential and Plan

Nov 13, 2023, 8:05 AM EST - 3 years ago

CORRECTION – Organovo Highlights FXR314 Combination Therapy Potential and Plan

Organovo Highlights FXR314 Combination Therapy Potential and Plan

Nov 8, 2023, 8:05 AM EST - 3 years ago

Organovo Highlights FXR314 Combination Therapy Potential and Plan

Organovo to Participate in the H.C. Wainwright Global Investment Conference

Sep 8, 2023, 12:46 PM EDT - 3 years ago

Organovo to Participate in the H.C. Wainwright Global Investment Conference

Organovo Advances Clinical Timelines for FXR314 and Provides Updates on NASH Phase 2 Data

Aug 23, 2023, 8:05 AM EDT - 3 years ago

Organovo Advances Clinical Timelines for FXR314 and Provides Updates on NASH Phase 2 Data

Organovo Announces FXR Program

Mar 21, 2023, 8:05 AM EDT - 3 years ago

Organovo Announces FXR Program

Organovo Announces Target Validation Ahead of Schedule, Accelerating Timeline for First Crohn's Disease Drug Candidates

Nov 15, 2022, 8:05 AM EST - 4 years ago

Organovo Announces Target Validation Ahead of Schedule, Accelerating Timeline for First Crohn's Disease Drug Candidates

Organovo to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

Sep 6, 2022, 8:20 AM EDT - 4 years ago

Organovo to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

Organovo Announces Postponement of Annual Meeting of Stockholders

Sep 6, 2022, 8:05 AM EDT - 4 years ago

Organovo Announces Postponement of Annual Meeting of Stockholders

Organovo Achieves 3D Tissue Model for Crohn's Disease

May 17, 2022, 8:05 AM EDT - 4 years ago

Organovo Achieves 3D Tissue Model for Crohn's Disease

UPDATE -- Organovo and BICO (CELLINK) Reach Licensing Agreement on Bioprinting Patents

Mar 1, 2022, 8:05 AM EST - 4 years ago

UPDATE -- Organovo and BICO (CELLINK) Reach Licensing Agreement on Bioprinting Patents

Organovo and BICO (CELLINK) Reach Licensing Agreement on Bioprinting Patents

Feb 23, 2022, 8:05 AM EST - 4 years ago

Organovo and BICO (CELLINK) Reach Licensing Agreement on Bioprinting Patents

Organovo Holdings, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Feb 18, 2022, 4:00 PM EST - 4 years ago

Organovo Holdings, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Organovo Welcomes New Sr. Vice President of Strategy and Business Development

Feb 18, 2022, 1:00 PM EST - 4 years ago

Organovo Welcomes New Sr. Vice President of Strategy and Business Development

Organovo Guides on Patent Portfolio and Successful IPR Defense of Two Patents

Feb 2, 2022, 12:00 PM EST - 4 years ago

Organovo Guides on Patent Portfolio and Successful IPR Defense of Two Patents

NetNinja
NetNinja Aug. 18 at 11:16 PM
$VIVS Just waiting for the inevitable R/S.
1 · Reply
itsStocksOver
itsStocksOver Aug. 18 at 8:28 PM
$VIVS bagged at 0.32 f this pos
1 · Reply
tomorrowsglory
tomorrowsglory Aug. 18 at 8:05 PM
$VIVS Low Volume Today!
0 · Reply
BigJuanOTC
BigJuanOTC Aug. 18 at 8:02 PM
$VIVS low volume snooze fest today…..
0 · Reply
Zboquid
Zboquid Aug. 18 at 8:01 PM
$VIVS
0 · Reply
valdekio
valdekio Aug. 18 at 7:14 PM
$VIVS Going down like a one legged hooker.
0 · Reply
ChillingTrader
ChillingTrader Aug. 18 at 5:35 PM
$VIVS 1. As of August 3, 2026, the Company's cash on hand was approximately $10.1 million 2.VivoSim expects FY27 revenue growth of over 500%, receives $5M milestone payment from Eli Lilly 3. VivoSim remains eligible for up to $45 million in additional milestone payments 4.4 million MC?????
0 · Reply
Zboquid
Zboquid Aug. 18 at 4:25 PM
$VIVS
0 · Reply
itsStocksOver
itsStocksOver Aug. 18 at 3:15 PM
$VIVS should run to 0.4 soon and then dump to rs
0 · Reply
Staker58
Staker58 Aug. 18 at 2:49 PM
$VIVS this one is toast
0 · Reply
Drew613
Drew613 Aug. 18 at 2:29 PM
$VIVS SL’s taken out
0 · Reply
BigJuanOTC
BigJuanOTC Aug. 18 at 2:12 PM
$VIVS lol reloaded yet? RS talk doesn’t start until after company meeting September 30th.
0 · Reply
johnrivers0110
johnrivers0110 Aug. 18 at 1:19 PM
$VIVS 🔺🩸😈 delist like adxt
0 · Reply
Staker58
Staker58 Aug. 18 at 1:08 PM
$VIVS who is still pumping this loser .2’s soon and RS
0 · Reply
GordoHLYK13
GordoHLYK13 Aug. 18 at 2:22 AM
$IGC $IVF $TRUG $UCL $VIVS When you stack $IGC against $VIVS, $UCL, $IVF, and $TRUG, IGC stands out on reverse-split history and its upcoming catalyst. IGC has had zero reverse splits in more than a decade, with its last one back in 2013, avoiding the repeated split/dilution cycle seen in many micro-caps. Now add the Phase 2 CALMA trial: IGC has randomized 160 patients, exceeding the original 146-patient target, with topline results expected in Q4 2026. That gives $IGC a potentially major clinical catalyst without the baggage of a recent reverse split. Clean structure + Phase 2 catalyst = IGC has one of the more compelling setups in this group. 🚀📈 @IGC am I correct ? Let’s goooo
0 · Reply
GordoHLYK13
GordoHLYK13 Aug. 18 at 2:20 AM
$IGC $IVF $TRUG $UCL $VIVS When you stack $IGC against $VIVS, $UCL, $IVF, and $TRUG, IGC stands out on reverse-split history and its upcoming catalyst. IGC has had zero reverse splits in more than a decade, with its last one back in 2013, avoiding the repeated split/dilution cycle seen in many micro-caps. Now add the Phase 2 CALMA trial: IGC has randomized 160 patients, exceeding the original 146-patient target, with topline results expected in Q4 2026. That gives $IGC a potentially major clinical catalyst without the baggage of a recent reverse split. Clean structure + Phase 2 catalyst = IGC has one of the more compelling setups in this group. 🚀📈
0 · Reply
NewsAndFilings
NewsAndFilings Aug. 17 at 11:26 PM
VivoSim Labs (NASDAQ: $VIVS ) Among $IGC, $IVF, $UCL, $TRUG as FDA-Backed Human-Based Testing Gains Momentum https://thestreetreports.com/vivosim-labs-nasdaq-vivs-among-igc-ivf-ucl-trug-as-fda-backed-human-based-testing-gains-momentum/
0 · Reply
Zboquid
Zboquid Aug. 17 at 10:03 PM
$VIVS Lame”O”💩
0 · Reply
Fox71
Fox71 Aug. 17 at 9:40 PM
$VIVS penny chasers!!
0 · Reply
JimmyOcarri
JimmyOcarri Aug. 17 at 8:56 PM
$VIVS $UAMY $SATL $URA $AGPU squad
0 · Reply
valdekio
valdekio Aug. 17 at 6:35 PM
$VIVS Great news and nothing.
0 · Reply
BigJuanOTC
BigJuanOTC Aug. 17 at 2:35 PM
$VIVS quite the write up over the weekend
0 · Reply